Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease

NCT04571372 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT04571372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04571372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease
Lead sponsor
Yonsei University
Phase
Observational
Overall status
Completed
Start date
August 14, 2020
Completion date
December 13, 2025
Enrollment
222 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe aortic stenosis or severe aortic regurgitation